Does Tamoxifen Stop Periods?

Tamoxifen can cause periods to become irregular or stop entirely in some premenopausal women, but it does not reliably shut down menstruation the way chemotherapy or ovarian suppression drugs do. The effect varies widely depending on age, whether chemotherapy was also given, and individual biology. What makes tamoxifen’s relationship with the menstrual cycle particularly confusing is that the drug can simultaneously push ovarian function in opposite directions, sometimes suppressing periods while actually boosting estrogen production behind the scenes.

How Tamoxifen Interacts With the Menstrual Cycle

Tamoxifen is a selective estrogen receptor modulator, meaning it blocks estrogen’s action in breast tissue while mimicking it in other parts of the body. In the brain, tamoxifen interferes with the normal feedback loop between the ovaries and the pituitary gland. Normally, rising estrogen levels signal the pituitary to ease off on follicle-stimulating hormone (FSH). Tamoxifen disrupts that signal, so the pituitary keeps pumping out FSH even when estrogen levels are already high. The result can be a hormonal environment that looks nothing like normal cycling: elevated FSH, elevated estrogen, and ovaries that may respond unpredictably.¹

This disrupted feedback can go in two very different directions. In some women, the confused signaling leads to anovulation and eventually amenorrhea, where periods stop. In others, the ovaries respond to the persistently high FSH by ramping up estrogen production to levels far beyond normal. Researchers have documented cases where tamoxifen drove estrogen to more than five times the upper limit of the normal range, sometimes causing ovarian cysts and endometrial thickening.² So tamoxifen is not simply “turning off” the ovaries. It is scrambling the hormonal conversation between the brain and the ovaries, and the outcome differs from person to person.

Who Is More Likely to Lose Their Period

Age is the strongest predictor. Women closer to their natural menopause are significantly more likely to develop amenorrhea on tamoxifen. A study of patients with invasive or pre-invasive breast cancer found that for every year of increasing age, the risk of developing amenorrhea within six months of starting tamoxifen rose by about a third.³ A woman starting tamoxifen at 45 has a much higher chance of her periods stopping than a woman starting at 30, partly because the older woman’s ovarian reserve is already declining and needs less of a push to tip into amenorrhea.

Prior chemotherapy dramatically changes the picture. Many breast cancer patients receive chemotherapy before starting tamoxifen, and chemotherapy itself is toxic to the ovaries. Women who become amenorrheic during chemotherapy and then move to tamoxifen often stay amenorrheic, making it look like tamoxifen caused the period loss when chemotherapy actually did the heavy lifting. This distinction matters clinically, because tamoxifen can mask ongoing ovarian function. One case report described a woman who was amenorrheic throughout five years of tamoxifen following chemotherapy, appeared postmenopausal on lab testing after stopping tamoxifen, and then resumed menstruating when she was switched to a different hormonal therapy.⁴ Her ovaries had been quietly functional the entire time, hidden by the amenorrhea.

For younger women who have not had chemotherapy, tamoxifen alone is less likely to stop periods. Some younger patients on tamoxifen continued to have ovulatory menstrual cycles throughout treatment.⁵ This is a crucial point, because many women assume that if they are on tamoxifen, they cannot get pregnant.

Periods Stopping Does Not Mean Ovaries Have Shut Down

One of the most important and least intuitive things about tamoxifen is that amenorrhea during treatment does not reliably indicate that the ovaries have stopped functioning. A woman can have no visible period while her ovaries are still producing estrogen, sometimes at elevated levels. In one study comparing amenorrheic and menstruating women on tamoxifen, estradiol levels were not significantly different between the two groups. FSH was higher in the amenorrheic group, suggesting the pituitary was working harder, but the ovaries were still responding.⁶

This has real consequences. Clinicians sometimes use amenorrhea as a rough marker for menopausal status when deciding whether to switch a patient from tamoxifen to an aromatase inhibitor, a class of drugs that only works in postmenopausal women. But if tamoxifen has been masking continued ovarian function, the switch can backfire. As the tamoxifen wears off and the aromatase inhibitor takes over, the ovaries, no longer held in check by tamoxifen’s disruptive effect on the feedback loop, can spring back to life. Researchers have specifically warned that the risk of ovarian function recovery needs to be considered before making this switch in women with chemotherapy-induced amenorrhea.⁷

Ovarian Hyperstimulation as the Opposite Problem

While some women lose their periods on tamoxifen, others experience the opposite extreme. Tamoxifen can act as a potent stimulator of ovarian function in premenopausal women. Case reports describe ovarian cyst formation, dramatically elevated estrogen, and endometrial hyperplasia during tamoxifen treatment alone.⁸ In one case, a patient’s total estrogen reached over 2,700 pg/mL, more than five times the top of the normal range, with a new ovarian cyst visible on ultrasound.²

This is not a common outcome, but it underscores how unpredictable tamoxifen’s ovarian effects are in premenopausal women. The same drug that causes amenorrhea in one patient can cause hyperstimulation in another. Ironically, tamoxifen is actually used at lower doses in fertility medicine precisely because of its ability to stimulate ovulation. The mechanism is the same feedback disruption described earlier, but in the fertility context, that ovarian stimulation is the goal rather than an unwanted side effect.

Pregnancy Risk During Treatment

Because tamoxifen does not reliably suppress ovulation, pregnancy is possible during treatment, even if your periods have become irregular or seem to have stopped. Tamoxifen is teratogenic, meaning it can cause birth defects, so effective contraception is essential for any premenopausal woman taking it. This catches some women off guard, because the combination of a cancer diagnosis, irregular periods, and a drug that sounds like it suppresses hormones can create a false sense that pregnancy is off the table.

Women who have become amenorrheic on chemotherapy before starting tamoxifen are in an especially tricky position. The chemotherapy may have damaged their ovarian reserve enough to cause permanent menopause, or the ovaries may recover. Tamoxifen’s disruption of the hormonal feedback loop makes standard blood tests for menopausal status unreliable during treatment. The safest approach is to assume fertility is possible until menopause is confirmed through testing after tamoxifen has been stopped for a sufficient period, something your oncologist can help determine.

What Happens When You Stop Tamoxifen

For many women, menstrual changes on tamoxifen are reversible once the drug is discontinued. Younger women who lost their periods on tamoxifen alone, without prior chemotherapy, frequently resume cycling. Even some women who were amenorrheic for the full five years of standard tamoxifen treatment have had periods return afterward.⁴ The likelihood of recovery depends heavily on age at the time tamoxifen is stopped and whether chemotherapy was also given. A woman who started tamoxifen at 32 and stops at 37 has a reasonable chance of her cycles returning. A woman who started at 47 and stops at 52 may find that natural menopause has arrived in the interim.

The timeline for recovery varies. Some women resume periods within weeks of stopping, while others take months. There is no reliable way to predict exactly when or whether cycles will return for any individual, which is part of what makes fertility planning after breast cancer treatment so challenging.

Bone Density Effects in Premenopausal Women

Tamoxifen’s menstrual effects connect to another concern that often surprises premenopausal patients: bone loss. In postmenopausal women, tamoxifen actually protects bone by acting like a weak estrogen. But in premenopausal women, the relationship flips. A trial comparing tamoxifen to placebo in healthy premenopausal women found that those on tamoxifen lost bone in the spine at a rate of about 1.4% per year, while women on placebo had a slight gain.⁹

A more recent systematic review and meta-analysis confirmed this pattern, finding a meaningful decrease in lumbar spine bone density in premenopausal women on tamoxifen after about three years of follow-up. Interestingly, women who received tamoxifen combined with chemotherapy or ovarian function suppression showed less bone loss at the spine than those on tamoxifen alone, a somewhat counterintuitive finding that may reflect the complex interplay between tamoxifen’s estrogen-like and anti-estrogen-like effects in different hormonal environments.¹⁰ For premenopausal women on long-term tamoxifen, periodic bone density monitoring is worth discussing with your treatment team.

When Bleeding Changes Need Investigation

Not all changes in menstrual pattern on tamoxifen are benign. Tamoxifen has well-documented effects on the uterine lining. In postmenopausal women, it acts as an estrogen agonist in the uterus, which can cause endometrial thickening, polyps, and in rare cases endometrial cancer. Premenopausal women are not immune to uterine effects either. Researchers in the Royal Marsden chemoprevention programme noted that premenopausal women who developed amenorrhea on tamoxifen may carry a particular risk for endometrial changes.¹¹

Any abnormal vaginal bleeding during tamoxifen treatment warrants prompt evaluation. This includes new bleeding after a period of amenorrhea, unusually heavy periods, bleeding between periods, or any postmenopausal bleeding. Clinicians have emphasized that these symptoms require investigation and careful follow-up.¹² The threshold for concern should be low, because tamoxifen’s protective effects in the breast come with a tradeoff of stimulatory effects in the uterus.

Combining Tamoxifen With Ovarian Suppression

Because tamoxifen alone does not reliably shut down ovarian function, oncologists sometimes add ovarian function suppression (OFS) for higher-risk premenopausal patients. OFS uses monthly or three-monthly injections of a GnRH agonist to chemically shut down the ovaries, or in some cases, surgical removal of the ovaries. The combination ensures that estrogen levels are truly lowered rather than paradoxically elevated.

A phase III trial comparing tamoxifen alone to tamoxifen plus OFS found that the combination came with a significant increase in menopausal symptoms, lower sexual activity, and worse quality-of-life scores at three years.¹³ This makes sense: you are layering a guaranteed chemical menopause on top of tamoxifen. Periods stop completely and reliably with OFS, which is part of the clinical point, but the side-effect burden is real. The decision about whether to add OFS involves weighing cancer recurrence risk against quality-of-life costs, and it is a conversation that varies based on tumor characteristics, age, and personal priorities.

Side Effects and Staying on Treatment

Menstrual disruption is just one piece of tamoxifen’s side-effect profile. Hot flashes, mood changes, vaginal dryness, joint pain, and weight changes are all commonly reported. The cumulative burden of these effects takes a measurable toll on treatment adherence. Data from the SOFT and TEXT trials showed that roughly one in five women discontinued tamoxifen early because of side effects.¹⁴ That rate was similar across treatment arms, including tamoxifen plus OFS and exemestane plus OFS, suggesting that the problem is not unique to tamoxifen but is a broader challenge of endocrine therapy in premenopausal women.

For women struggling with tamoxifen’s effects on their cycle and overall well-being, early and honest conversations with their oncology team matter. Dose adjustments, supportive medications for specific symptoms, or switches to alternative endocrine therapies are all options worth exploring rather than simply stopping treatment.

Sexual Functioning and Amenorrhea

One concern women often raise is how the loss of their period and the hormonal upheaval of tamoxifen affect sexual function. The evidence here is more reassuring than you might expect. A study of young breast cancer survivors found that tamoxifen use did not worsen sexual functioning in the short term. Women currently on tamoxifen actually trended toward fewer sexual problems compared to non-users, regardless of whether they were amenorrheic.¹⁵ That said, individual experiences vary enormously. Vaginal dryness, which is a common tamoxifen side effect, can directly affect sexual comfort, and the psychological weight of a cancer diagnosis and forced hormonal changes complicates the picture in ways a questionnaire cannot fully capture.

The broader point is that tamoxifen’s menstrual effects do not exist in isolation. They are tangled up with the drug’s actions across the entire body, its interactions with prior treatments, and the emotional reality of managing a breast cancer diagnosis. Whether your periods stop, persist, or become chaotic on tamoxifen depends on a web of factors that no simple yes-or-no answer can cover. What remains consistent across the research is that the absence of periods should never be taken as proof that the ovaries have gone quiet, and any unexpected bleeding deserves medical attention.